GATHER, NCT01414855: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma |
|
|
| Completed | 2 | 100 | US | obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine | Genentech, Inc. | Lymphoma, B-Cell | 12/13 | 12/16 | | |
NCT01889797: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma |
|
|
| Terminated | 2 | 32 | US | Arm A: Rituximab, IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan, NSC# 687451, Arm B: GA101, Obinutuzumab, RO5072759, huMAB | PrECOG, LLC., Genentech, Inc. | Indolent Non-Hodgkin's Lymphoma | 04/16 | 08/16 | | |